Low-dose tacrolimus for intractable myasthenia gravis.
We treated two patients suffering from intractable myasthenia gravis (MG) with low-dose tacrolimus plus prednisolone. Both patients showed significant improvement of myasthenic signs, accompanied by suppressed serum anti-acetylcholine receptor antibody, waning in compound muscle action potential by repetitive nerve stimulation and IL-2 production by peripheral blood mononuclear cells. Low-dose tacrolimus plus prednisolone is a promising therapeutic regimen for intractable MG.
Yoshikawa
Hiroaki
H
Health Service Center, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa 920-1192, Japan. hiroaki@kenroku.kanazawa-u.ac.jp
Mabuchi
Kazunori
K
Yasukawa
Yoshihiro
Y
Takamori
Masaharu
M
Yamada
Masahito
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001323:Autoantibodies / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D011239:Prednisolone; D016559:Tacrolimus